Handbook of Chemistry, Biochemistry and Biology: New Frontiers

0435689 - ÚMCH 2015 RIV US eng M - Část monografie knihy
Horák, Daniel - Gumargalieva, K. Z. - Zaikov, G. E. - Artsis, M. I. - Madyuskina, L. L.
Hydrogels in endovascular embolization Part V. Antitumor agent methotrexate-containing p(HEMA).
Handbook of Chemistry, Biochemistry and Biology: New Frontiers. Hauppauge: Nova Science Publishers, 2010 - (Shishkina, L.; Zaikov, G.; Goloschapov, A.), s. 39-50. ISBN 978-1-60741-861-0
Výzkumný záměr: CEZ:AV0Z40500505
Klíčová slova: antitumor agent * hydrogels * p(HEMA)
Kód oboru RIV: CD - Makromolekulární chemie

This paper allows us to assume that emboli made from the modified p(HEMA) hydrogel can be loaded with methotrexate, one of the most frequently used cytostatics. Such a simple MTX-fixation to a p(HEMA)-Hex carrier has the advantage that the pharmacological activity of the drug remains unchanged. The use of p(HEMA)-Hex-MTX hydrogel emboli should enable us to achieve a maximum concentration and a prolonged effect of the cytostatic in the embolized region (tumor) while reducing its concentration in other tissues of the organism at the same time. Thus, there is a prospect of the targeted local palliative cytostatic effect of the drug on the tumor and of prevention of the possible haematogenic formation of metastases, along with a decreased blood supply to this zone or to the whole organ. In other words, the site-specific function of the released antitumor drug could be combined with the endovascular occlusion of blood supply to the tumor tissue.
Trvalý link: http://hdl.handle.net/11104/0240165